Twist Bioscience (NASDAQ:TWST) Insider Sells $1,274,898.75 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 14,205 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the transaction, the insider owned 105,141 shares of the company’s stock, valued at $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dennis Cho also recently made the following trade(s):

• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The stock was sold at an average price of $87.32, for a total value of $30,212.72.
• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The stock was sold at an average price of $69.84, for a total value of $28,075.68.

Twist Bioscience Price Performance

TWST stock opened at $99.84 on Monday. The business has a 50 day moving average of $67.01 and a 200 day moving average of $51.57. The firm has a market cap of $6.22 billion, a PE ratio of -75.07 and a beta of 2.23. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $104.23. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. During the same period last year, the firm posted ($0.66) earnings per share. The company’s revenue was up 19.3% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the business. Stifel Financial Corp raised its position in Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after buying an additional 271 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in shares of Twist Bioscience by 1.2% during the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after acquiring an additional 305 shares during the last quarter. CWM LLC grew its stake in shares of Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after acquiring an additional 407 shares during the period. California State Teachers Retirement System grew its stake in shares of Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after acquiring an additional 442 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TWST. Piper Sandler initiated coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective on the stock. Guggenheim lifted their target price on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a report on Friday, May 22nd. Finally, Canaccord Genuity Group assumed coverage on shares of Twist Bioscience in a research report on Monday, June 15th. They set a “buy” rating and a $90.00 price target for the company. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.60.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.